Skip to main content

Advertisement

Log in

Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy–Thrombocytopenia (FACT-Th) questionnaire

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The specific concerns of people with low platelet counts (thrombocytopenia) have not been characterized well in the literature and as a result proper measurement of patient-reported concerns is lacking. We report on the development and validation of questions specifically targeted to patients with thrombocytopenia that can be added to the more general concerns in the Functional Assessment of Cancer Therapy-General.

Materials and methods

An 18-item FACT-Thrombocytopenia Subscale (ThS) was rated and evaluated by thrombocytopenic patients at baseline during a validation study of 40 thrombocytopenic and 43 nonthrombocytopenic cancer patients. To evaluate responsiveness, patients completed a battery of self-report measures including the FACT-Th and were followed up for change in platelet count over 2 weeks.

Results

All subscales and aggregated scores showed high internal consistency at initial assessment and at retesting. Convergent and divergent validity were demonstrated by predicted relationships between FACT-Th subscales and mood, mental and physical component scores of the SF-36, and social desirability. The ThS differentiated patients with low platelets from those with normal platelet counts and good performance from poor performance status patients.

Conclusion

The FACT-Th is a reliable and valid measure for assessing the impact of thrombocytopenia on patients’ lives. It can distinguish cancer patients with and without thrombocytopenia and is responsive to increase in platelet count over time. The FACT-Th may therefore prove useful as a measure of self-reported symptoms and concerns related to thrombocytopenia in clinical trials evaluating new pharmacologic agents and/or platelet transfusion practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Scheme 1

Similar content being viewed by others

References

  1. Bastion Y, Blay J, Divine M, Brice P, Bordessoule D, Sebban C, Blanc M, Tilly H, Lederlin P, Deconinck E, Salles B, Dumontet C, Briere J, Coiffier B (1997) Elderly patients with aggressive non-Hodgkin’s lymphoma: disease presentation, response to treatment, and survival-a Groupe D’Etude Des Lymphomes De L’Adulte study on 453 patients older than 69 years. J Clin Oncol 15:2945–2953

    PubMed  CAS  Google Scholar 

  2. Cella D (1997) Manual of the Functional Assessment of Chronic Illness Therapy (FACIT scales), version 4. Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, Evanston, IL, USA

  3. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579

    PubMed  CAS  Google Scholar 

  4. Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297–334

    Article  Google Scholar 

  5. Crowne DP, Marlowe D (1960) A new scale of social desirability independent of psychopathology. J Consult Psychol 24:344–354

    Article  Google Scholar 

  6. Demetri GD (2001) Targeted approached for the treatment of thrombocytopenia. Oncologist 6:15–23

    Article  PubMed  CAS  Google Scholar 

  7. Elting LS (1999) Chemotherapy-induced thrombocytopenia and the use of prophylactic platelet transfusions and growth factors. In: 11th MASCC international symposium: supportive care in cancer, Nice, France, 18–20 February 1999

  8. Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, Laiho E, Kanesan K, Cantor SB, Benjamin R (2001) Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19:1137–1146

    PubMed  CAS  Google Scholar 

  9. Elting LS, Cantor SB, Martin CG, Hamblin L, Kurtin D, Rivera E, Vadhan-Raj S, Benjamin R (2003) Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 97:1541–1550

    Article  PubMed  Google Scholar 

  10. Engel C, Loeffler M, Franke H, Schmitz S (1999) Endogenous thromboprotein serum levels during multicycle chemotherapy. Br J Haematol 105:832–838

    Article  PubMed  CAS  Google Scholar 

  11. Fraboni M, Cooper D (1989) Further validation of three short forms of the Marlowe-Crowne scale of social desirability. Psychol Rep 65:595–600

    Google Scholar 

  12. Goodnough LT, DiPersio JF (2002) Issues in the management of cancer-related thrombocytopenia. Oncology 16:1558–1567

    PubMed  Google Scholar 

  13. Linacre JM (1994) Sample size and item calibration stability. Rasch Meas Trans 7:328

    Google Scholar 

  14. Linacre JM (2002) WINSTEPS. Chicago

  15. Ludwin D, Sacks P, Lynch S, Jacobs P, Bezwoda W, Bothwell TH (1974) Auto-immune haematological complications occurring during the treatment of malignant lymphoproliferative disease. S Afr Med J 48:2143–2145

    PubMed  CAS  Google Scholar 

  16. Malone D, Sullivan S, Black D, Stergachis A (1995) The cost of treating chemotherapy induced thrombocytopenia (in the proceedings of the American Society of Clinical Oncology). J Clin Oncol 14:305

    Google Scholar 

  17. McNair DM, Lorr M, Droppleman LF (1992) Profile of Mood States (POMS). Educational and Industrial Testing Service, San Diego, CA, USA

    Google Scholar 

  18. Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBrecque J, Erder H, Schulman KA (2000) Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol 64:251–256

    Article  PubMed  CAS  Google Scholar 

  19. Nunnally JC, Bernstein IH (1994) Psychometric theory. McGraw-Hill, New York

    Google Scholar 

  20. Rubenstein EB, Elting L (1998) Incorporating new modalities into practice guidelines: platelet growth factors. Oncology 12:381–386

    PubMed  CAS  Google Scholar 

  21. Rust DM, Wood LS, Battiato LA (1999) Oprelvekin: an alternative treatment for thrombocytopenia. Clin J Oncol Nurs 3:57–62

    PubMed  CAS  Google Scholar 

  22. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, Troner MB, Wagnon AH, American Society of Clinical Oncology (2001) Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519–1538

    PubMed  CAS  Google Scholar 

  23. Schiller JH, Ritch PS, Storer B, Trump DL (1989) A pilot study of short-course, high-dose cytosine arabinoside, etoposide, and cisplatin in refractory, aggressive-histology, non-Hodgkin’s Lymphomas. Am J Clin Oncol 12:502–506

    Article  PubMed  CAS  Google Scholar 

  24. Tepler I, Elias L, Smith JW, Hussein M, Rosen G, Chang AYC, Moore JO, Gordon MS, Kuca B, Beach KJ, Loewy JW, Garnick MB, Kaye JA (1996) A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607–3614

    PubMed  CAS  Google Scholar 

  25. Ware JE, Snow KK, Kosinski M (2000) SF-36 health survey: manual and interpretation guide. QualityMetric, Lincoln, RI, USA

    Google Scholar 

  26. Webster K, Odom L, Peterman AH, Lent L, Cella D (1999) The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 the core questionnaire. Qual Life Res 8:604

    Google Scholar 

  27. Wright BD, Tennant A (1996) Sample size again. Rasch Meas Trans 9:468

    Google Scholar 

  28. Zubrod C, Schneiderman M, Frei E III, Brindley C, Gold GL, Shnider B, Oviedo R, Gorman J, Jones R Jr, Jonsson U, Colsky J, Chalmers T, Ferguson B, Dederick M, Holland J, Selawry O, Regelson W, Lasagna L, Owens AH (1960) Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene. J Chronic Dis 11:7–33

    Article  Google Scholar 

Download references

Acknowledgement

This work was supported by an investigator-initiated research grant from the Pharmacia Corporation. The manuscript was written in collaboration with Dr. Timothy Hunt who was employed by Pharmacia at the time of collaboration.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David Cella.

Appendix

Appendix

FACT-Th© additional concerns

Below is a list of statements that other people with your illness have said are important. By circling one (1) number per line, please indicate how true each statement has been for you during the past 7 days.

 

 

Not at all

A little bit

Some-what

Quite a bit

Very much

An5

I have energy

0

1

2

3

4

An7

I am able to do my usual activities

0

1

2

3

4

Th1

I bleed easily

0

1

2

3

4

Th2

I bruise easily

0

1

2

3

4

Th3

I worry about problems with bruising or bleeding

0

1

2

3

4

Th5

I am bothered by nosebleeds

0

1

2

3

4

Th7

I am bothered by pinpoint bruising beneath my skin

0

1

2

3

4

Th8

I am bothered by blood in my urine or stool

0

1

2

3

4

Th10

I avoid or limit physical activity (because of concern with bleeding or bruising)

0

1

2

3

4

Th12

I am frustrated by not being able to do my usual activities

0

1

2

3

4

Th13

I worry that my treatment will be delayed (because of low blood counts)

0

1

2

3

4

The items below are excluded from the 11-item ThS

H7

I feel fatigued

0

1

2

3

4

Th4

I worry about the possibility of serious bleeding

0

1

2

3

4

Th6

I am bothered by bleeding in my gums or mouth

0

1

2

3

4

Th9

I am inconvenienced by platelet transfusions

0

1

2

3

4

Th11

I avoid or limit social activity (because of concern with bleeding or bruising)

0

1

2

3

4

Th14

I worry that my treatment dose will be reduced (because of low blood counts)

0

1

2

3

4

Th15

For women only: I am bothered by vaginal bleeding

0

1

2

3

4

  1. © Copyright 2005, DAvid Cella, Ph.D

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cella, D., Beaumont, J.L., Webster, K. . et al. Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy–Thrombocytopenia (FACT-Th) questionnaire. Support Care Cancer 14, 1220–1231 (2006). https://doi.org/10.1007/s00520-006-0102-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-006-0102-1

Keywords

Navigation